A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

• Published in: Journal of hematology and oncology Vol. 11; no. 1; pp. 141 - 8
• Main Authors: Zhao, Wan-Hong, Liu, Jie, Wang, Bai-Yan, Chen, Yin-Xia, Cao, Xing-Mei, Yang, Yun, Zhang, Yi-Lin, Wang, Fang-Xia, Zhang, Peng-Yu, Lei, Bo, Gu, Liu-Fang, Wang, Jian-Li, Yang, Nan, Zhang, Ru, Zhang, Hui, Shen, Ying, Bai, Ju, Xu, Yan, Wang, Xu-Geng, Zhang, Rui-Li, Wei, Li-Li, Li, Zong-Fang, Li, Zhen-Zhen, Geng, Yan, He, Qian, Zhuang, Qiu-Chuan, Fan, Xiao-Hu, He, Ai-Li, Zhang, Wang-Gang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20.12.2018; BioMed Central; BMC
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antigen receptors, T cell; Antigens; Aphasia; Aspartate aminotransferase; B-Cell Maturation Antigen - metabolism; BCMA; Blood cancer; Cancer; CAR T; Care and treatment; Cellular therapy; Chimeric antigen receptor; Chimeric antigen receptors; Cyclophosphamide; Cytokines; Epitopes; Female; Genetic aspects; Health risk assessment; Hematology; Humans; Leukemia; Leukopenia; Lymphocytes; Lymphocytes B; Lymphocytes T; Lymphoma; Male; Medical prognosis; Middle Aged; Minimal residual disease; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - pathology; Neurotoxicity; Oncology; Patients; Physiological aspects; Receptors; Receptors, Chimeric Antigen - metabolism; Refractory; Relapsed; Remission Induction; Safety; Studies; T cells; Thrombocytopenia; Working groups; Young Adult; China; Refractory; BCMA; Chimeric antigen receptor; CAR T; Relapsed; Multiple myeloma

Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell maturation antigen epitopes, in patients with relapsed/refracto...